Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 2/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.63 |
| ▸ | ACACB | O00763 | 16/20 | 0.55 |
| ▸ | ACACA | Q13085 | 16/20 | 0.55 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14222025 | 0.84 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL10169907 | 0.83 | NPC1 (0.51) | ABCC1ABCG2ACACBACACANPC1 | |
| SCHEMBL8329259 | 0.81 | ABCC1 (0.63) | ABCC1ABCG2ACLY | |
| SCHEMBL3498296 | 0.80 | ABCC1 (0.77) | ABCC1ABCG2ACACBACLYNPC1 | |
| SCHEMBL4397587 | 0.79 | ACACB (0.55) | ACACBACACA | |
| SCHEMBL4397599 | 0.79 | ACACB (0.55) | ACACBACACA | |
| SCHEMBL2210050 | 0.79 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL4258404 | 0.78 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL14042026 | 0.78 | ACACB (0.74) | ACACBACACA | |
| SCHEMBL4261302 | 0.77 | ACACB (0.64) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981904-B2 | Acetyl CoA carboxylase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7981904-B2 | Acetyl CoA carboxylase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7981904-B2 | Acetyl CoA carboxylase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | ABCC1 1490/4885ABCG2 2813/4885ACACB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.